Triple GIP/GLP-1/Glucagon Receptor Agonist
Retatrutide
Retatrutide is a novel triple-acting receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This investigational compound represents the next frontier in incretin-based research. Synthesized to ≥99% purity.
- Molecular Weight: ~4,600 g/mol
- Sequence: Modified triple-agonist peptide
- Purity: ≥99% (HPLC verified)
- Storage: -20°C, lyophilized
Total
$349.00
+ $25.00 Flat Rate Shipping
For research use only. By purchasing, you agree to our terms of service.
Common Schedule
Retatrutide Titration Timeline
Gradually increasing your dose helps minimize side effects and allows your body to adjust. Consult your healthcare provider for personalized guidance.
Weeks 1–4
1.0 mg
Starting dose
Weeks 5–8
2.0 mg
Per week dose
Weeks 9–12
4.0 mg
Per week dose
Weeks 13–16
8.0 mg
Per week dose
Week 17+
12.0 mg
Maintenance
Weeks 1–4Starting dose
1.0 mg
Weeks 5–8Per week dose
2.0 mg
Weeks 9–12Per week dose
4.0 mg
Weeks 13–16Per week dose
8.0 mg
Week 17+Maintenance
12.0 mg